01:41 PM EST, 12/13/2024 (MT Newswires) -- Repare Therapeutics ( RPTX ) reported Thursday results from a phase 1 trial of cancer drugs lunresertib and camonsertib that disappointed investors.

The lunresertib and camonsertib combination achieved a 25.9% objective response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer in the trial. The study included heavily pretreated patients.

Shares slumped 57% following a surge in intraday trading volume to over 3.6 million from a daily average of about 165,000.

Inovio Pharmaceuticals ( INO ) said Friday it priced an offering of 10 million shares and accompanying warrants to purchase the same number of shares at $3 per share and accompanying warrant.

Shares slumped 39%, with intraday trading volume at over 7.8 million versus the stock's daily average of about 387,000.

Candel Therapeutics ( CADL ) sank past 30% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.

More than 15.1 million shares traded intraday compared with a daily average of about 2.4 million.

Price: 1.71, Change: -2.26, Percent Change: -56.95